Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
See our Community Guidelines at bit.ly/3c5Pztz.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 201 Haskins Way,
- Industry
- Biotechnology
- Website
- graphitebio.com
- Keywords
- biotechnology, research, clinical development, sickle cell disease, CRISPR, gene therapy, gene editing.
- HQ
- South San Francisco, CA
Graphite Bio Questions
Graphite Bio's website is graphitebio.com
Graphite Bio's LinkedIn profile is https://www.linkedin.com/company/graphitebio
Graphite Bio has
2 employees.
View email and phone details for 2
employees at Graphite Bio.
Graphite Bio's industry is
Biotechnology
Graphite Bio's top competitors are
Marea Therapeutics,
Allogene Therapeutics,
Scribe Therapeutics,
Kyverna Therapeutics,
Lenz Therapeutics,
Arsenal Biosciences, Inc.,
Xaira Therapeutics,
Caribou Biosciences,
Sana Biotechnology, Inc.,
Tarsus Pharmaceuticals, Inc..
Graphite Bio's categories are Biotechnology
Graphite Bio's founding year is 2020
